Consensus Outlook: Multiple Sclerosis -

Charting the Future Multiple Sclerosis Market Landscape

Over the next five years, the global multiple sclerosis (MS) market is set to grow from $14.4 billion in 2012 to $18.3 billion in 2017. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.

Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:

  • An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance
  • A detailed forecast data analysis spreadsheet model comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017
  • Timely event-driven market forecast report and data analysis updates over the next 12 months

Understand the Unique Benefits of Consensus Outlook

  • Evaluate future sales forecasts and predicted market growth
  • Map your market parameters and chart commercial prospects
  • Assess market share by company and product
  • Tailor your strategic and investment focus based on the competition
  • Set proactive launch and branding strategies
  • Keep up with event-driven market data updates

Content Highlights

  1. Forecast Data Model (Excel)
    • Market size
    • Product sales
    • Company forecast
    • Mechanism of action
    • Future Events
  2. Forecast Analysis Report (PDF)
    • FirstWord Analysis Highlights
    • Research Methodology
    • Multiple Sclerosis Marketplace
    • Key Multiple Sclerosis Developers
    • Multiple Sclerosis Class Dynamics
    • Tecfidera (dimethyl fumarate; Biogen) forecast
    • Aubagio (teriflunomide; Sanofi) forecast
    • Gilenya (fingolimod; Novartis Mitsubishi Tanabe) forecast
    • Tysabri (natalizumab; Biogen) forecast
    • Copaxone (glatiramer acetate; Teva) forecast
    • Avonex (interferon beta-1a; Biogen) forecast
    • Betaseron (interferon beta-1b; Bayer) forecast
    • Rebif (interferon beta-1a; Merck Serono) forecast
    • Extavia (interferon beta-1b; Novartis) forecast
    • Lemtrada (alemtuzumab; Genzyme/Sanofi) forecast
    • Laquinimod (Teva/Active Biotech) forecast
    • Daclizumab HYP (Biogen/AbbVie) forecast
    • Ocrelizumab (Biogen/Roche/Biogen) forecast